Inositol (Myo-Inositol, D-Chiro-Inositol)
Inositol is a sugar-like nutrient your body makes from glucose and also takes in from food (citrus fruits, beans, grains, nuts — roughly 1-2 g/day from a typical diet). It is sold in the UK as a food supplement, principally for women with polycystic ovary syndrome (PCOS) and for subfertility — talk to your GP, gynaecology team, or fertility clinic about whether it's right for you, because PCOS care is multifaceted and inositol is one optional adjunct, not a cure. The most studied form is myo-inositol (MI). A second form, D-chiro-inositol (DCI), is also relevant — most modern trial protocols use a 40-to-1 MI:DCI ratio, matching the natural ratio in human tissues. UK fertility specialists increasingly include myo-inositol in PCOS preconception advice; the Cochrane Showell 2018 review (PMID 30570133) graded the evidence as low-to-very- low quality but a 2023 meta-analysis (Greff 2023, PMID 36703143, 26 RCTs, n=1,691) reported inositol was non-inferior to metformin for menstrual-cycle normalisation, with reductions in BMI, fasting glucose, and free testosterone. There are NO UK-authorised health claims for inositol — its regulatory status is food supplement only. The single most important safety point: AVOID inositol if you take lithium for bipolar disorder. Supplementing inositol opposes lithium's mood-stabilising mechanism and bipolar relapse has been reported. For pregnancy, talk to your midwife or obstetrician before adding — UK NICE does NOT yet include inositol in the routine antenatal pathway, although a Cochrane review (Crawford 2015, PMID 26678256) of four Italian trials suggested antenatal myo-inositol may reduce gestational-diabetes incidence in high-risk women. Camden does NOT currently retail a single- active inositol SKU.
Camden Medicals editorial · Last reviewed 12 May 2026 · Next review May 2027
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Other
- Typical daily dose
- PCOS / subfertility: 2-4 g/day myo-inositol, often as 2 g + 50 mg D-chiro-inositol in the 40:1 ratio (Inofolic® standard), 2× daily. OCD / panic disorder trial protocols: 12-18 g/day myo-inositol — substantially higher than PCOS doses. Gestational-diabetes prevention trials: 4 g/day myo-inositol from first trimester onward.
- Top use evidence
- Strong
On this page
What it is
Inositol behaves like a sugar but is actually a sugar alcohol — your body uses it to build cell membranes and to relay messages inside cells, particularly the messages that come from the insulin receptor. Your body makes its own inositol from glucose, and you also get small amounts from food (citrus fruits, beans, whole grains, nuts) — typical UK dietary intake is around 1-2 g/day, sufficient for general needs. Supplementation is a clinical-adjunct conversation, mostly for PCOS or fertility, not a general-population nutrient gap.
The chemistry detail: inositol exists in nine stereoisomers (different 3D arrangements of the same atoms) of the cyclic six-carbon sugar alcohol cyclohexane-1,2,3,4,5,6-hexol. The most abundant in human tissues is myo-inositol (MI) — present as free MI and incorporated into phosphatidylinositol (a membrane phospholipid) and inositol phosphate second messengers (IP3, IP4, IP5, IP6). The second-most-relevant for supplementation is D-chiro-inositol (DCI) — present at much lower abundance in human tissues (~40-fold less than MI) and concentrated in glycogen-storage and insulin-target tissues.
Inositol biosynthesis: humans can synthesise myo-inositol from glucose-6-phosphate via inositol-1-phosphate synthase (the same pathway organisms used since the very early eukaryotic period). Endogenous synthesis plus dietary intake (1-2 g/day from a typical Western diet — citrus fruits, beans, grains, nuts) provides usual nutrient supply. D-chiro-inositol is generated principally from myo-inositol via insulin-stimulated epimerase activity in target tissues; it is not present in food in meaningful amounts.
Commercial supplement preparations:
- Pure myo-inositol powder (typical dose 2-4 g per serving, 2× daily for PCOS protocols).
- 40:1 myo-inositol : D-chiro-inositol blend (Inofolic®, Lo.Li. Pharma standard) — the physiological ratio. Typical dose 2 g MI + 50 mg DCI, 2× daily.
- Inofolic Plus (Lo.Li. Pharma) — myo-inositol + folic acid combination for preconception and pregnancy use.
- Pure D-chiro-inositol — less common; dose-narrow-therapeutic-window concern in some literature.
- Combination supplements with magnesium, B vitamins, alpha-lipoic acid, or chromium for "metabolic / PCOS support" framing.
UK regulatory tier: food supplement only. EFSA Article 13 evaluations are on hold. UK NHS / NICE pathways for PCOS (CKS Polycystic Ovary Syndrome) and subfertility (NG121) acknowledge inositol as a non-licensed supplement that some patients choose to use; UK fertility specialist practice increasingly includes inositol in preconception advice for PCOS.
Note on terminology: "Inositol" alone on a label most commonly means myo-inositol, but the species should be declared. "Hexaphosphate inositol" / "phytate" / "IP6" is a different molecule (inositol with six phosphate groups attached) sold as a separate supplement category for cancer-prevention marketing claims that are NOT authorised in the UK and are outside this entry's scope.
At a glance
- Sugar-alcohol nutrient your body makes from glucose; small amounts also from citrus, beans, grains, nuts. UK food supplement with NO UK-authorised health claims.
- Two forms matter for supplementation: myo-inositol (MI) and D-chiro-inositol (DCI). Most modern PCOS / fertility protocols use a 40:1 MI:DCI ratio matching the physiological tissue ratio. Pure-MI products are also widely sold.
- Strongest evidence in PCOS: Greff 2023 meta-analysis (PMID 36703143, 26 RCTs, n=1,691) — inositol non-inferior to metformin for cycle normalisation, with reductions in BMI, free testosterone, glucose. Cochrane Showell 2018 (PMID 30570133) — uncertain on IVF live birth, evidence "very low quality".
- AVOID with lithium. Inositol opposes lithium's mood-stabilising mechanism; bipolar relapse has been reported. Tell your psychiatrist about ANY supplement use.
- Pregnancy: a Cochrane review of four Italian trials (Crawford 2015, PMID 26678256) suggested antenatal myo-inositol reduces gestational-diabetes incidence in high-risk women (RR 0.43). UK NICE NG3 does NOT yet include it. Talk to your midwife or obstetrician before adding.
- Mood / OCD / panic disorder evidence: small early trials used 12-18 g/day myo-inositol — much higher than PCOS doses. UK NICE pathways for these conditions do NOT include inositol; NHS first-line is talking therapies + SSRI / SNRI antidepressants.
What people use it for
Women with PCOS-related subfertility considering inositol as a non-licensed adjunct
Cochrane Showell 2018 systematic review (CD012378) on myo-inositol for women with subfertility (mostly PCOS) reported modest improvements in clinical pregnancy rate with limited-quality evidence. UK fertility specialist practice increasingly includes myo-inositol (typically 2 g + 50 mg D-chiro-inositol, 2× daily, in the 40:1 ratio) as a non-licensed adjunct for PCOS patients undergoing IVF or clomiphene cycles. Talk to the fertility team managing your treatment before adding. [12,1]
Some evidenceLimitedWomen with PCOS managing menstrual irregularity and metabolic symptoms outside fertility context
Some trial evidence for myo-inositol on menstrual cyclicity, hyperandrogenism markers, and insulin sensitivity in PCOS. UK NICE CKS Polycystic Ovary Syndrome notes inositol as a non-licensed supplement; standard NHS PCOS care is lifestyle (weight management) plus combined oral contraceptive (for menstrual regulation and androgen excess) plus metformin (where insulin resistance is documented and lifestyle is insufficient). Inositol can be discussed with the GP or gynaecology team alongside the licensed pathway. [1]
Some evidenceLimitedPregnant women at high risk of gestational diabetes
Some evidence (Crawford 2015 Cochrane review and subsequent Italian trials) supports antenatal myo-inositol supplementation reducing gestational-diabetes incidence in high-risk women (PCOS, family history, BMI ≥30, prior GDM). UK NICE NG3 (Diabetes in pregnancy) does not currently include inositol in routine antenatal pathway; specialist obstetric clinics may discuss case-by-case. Talk to your midwife or obstetrician before adding any supplement in pregnancy. [13,2]
Some evidenceLimitedAdults considering inositol for OCD, panic disorder, or generalised anxiety
UK NICE pathways for OCD (CG31), panic disorder (CG113), and generalised anxiety (CG113) do NOT include inositol. Small early trials (Levine 1995, Fux 1996) at 12-18 g/day myo-inositol reported modest reductions in OCD / panic symptom scores; subsequent larger trials have not consistently replicated the effects. UK NHS first-line treatment is talking therapies + SSRI / SNRI antidepressants depending on diagnosis. Self-supplementing inositol for diagnosed OCD or panic disorder is not the appropriate pathway. [14,15]
Popular, not provenInsufficientAdults with bipolar disorder treated with lithium
CONTRAINDICATED. Inositol supplementation opposes lithium's mood-stabilising mechanism by replenishing the inositol pool that lithium therapy depletes. Bipolar-disorder relapse on lithium has been reported after adding inositol. Tell your psychiatrist about ANY supplement use; do not self-supplement inositol. [5]
Some evidenceStrongAdults considering inositol for mood / anxiety while NOT on lithium
UK NICE pathways for mood and anxiety disorders do not include inositol. The trial evidence is small and inconsistent. Talk to your GP about clinically-evidenced UK NHS pathways (talking therapies, antidepressants where indicated). [16]
Popular, not provenInsufficient
How it works
Inositol's biological roles are best understood as second-messenger signalling and membrane-phospholipid chemistry, with the supplementation-relevant context being insulin signalling.
Phosphatidylinositol and inositol phosphates — second messenger system. Phosphatidylinositol-4,5-bisphosphate (PIP2) is the membrane phospholipid that, on cleavage by phospholipase C, releases inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) — two of the most important second messengers in cell signalling. IP3 binds the IP3 receptor on the endoplasmic reticulum to release intracellular calcium; DAG activates protein kinase C. The system operates downstream of receptor tyrosine kinases (insulin receptor, IGF-1 receptor, FGF receptor) and G-protein-coupled receptors (α1-adrenergic, muscarinic, vasopressin).
Insulin signalling — the PCOS-relevant mechanism. Inositol phosphoglycans (IPGs) — chiro-inositol-containing IPG (DCI-IPG) and myo-inositol-containing IPG (MI-IPG) — act as second messengers for insulin. PCOS is characterised by insulin resistance plus hyperandrogenism; the prevailing mechanistic hypothesis (Larner 2002, Nestler 2007) is that PCOS-affected ovarian tissue has an MI-to-DCI imbalance — high DCI synthesis at the expense of MI, with downstream effects on FSH-stimulated follicular development. Supplemental MI restores intracellular MI levels; the 40:1 MI:DCI ratio matches the physiological tissue ratio.
Folliculogenesis and oocyte quality. Myo-inositol is the principal inositol form in follicular fluid and oocytes. Folliculogenesis efficiency and oocyte quality are sensitive to follicular-fluid MI concentrations; supplemental MI in PCOS women has been associated with improved oocyte morphology in IVF protocols.
Mood / anxiety / OCD — inositol depletion hypothesis. The lithium-stabilising-mood mechanism is partly thought to operate through inositol depletion (lithium inhibits inositol monophosphatase, reducing free inositol regeneration in the brain). Berridge 1989 and subsequent work proposed that excess inositol second-messenger signalling underlies mood and obsessive-compulsive symptoms, and that supplemental inositol could (paradoxically) help anxiety / OCD by saturating the system in a different way. Levine 1995, Fux 1996, and other small early trials at 12-18 g/day myo-inositol reported modest reductions in OCD and panic-disorder symptom scores; subsequent larger trials have not consistently replicated the effects. UK NICE pathways for OCD (CG31) and panic disorder (CG113) do not include inositol.
The lithium interaction — load-bearing. The lithium-inositol-depletion mechanism is the basis for the inositol-lithium interaction warning. Adding supplemental inositol opposes lithium's mood-stabilising action by replenishing the inositol pool that lithium therapy is depleting. Bipolar-disorder relapse on lithium has been reported after adding myo-inositol supplements. CONTRAINDICATED in bipolar disorder treated with lithium without specialist input.
Insulin sensitisation outside PCOS. Trial evidence for inositol in type 2 diabetes glycaemic control is small (Pintaudi 2016 meta-analysis suggestive of modest HbA1c improvement). UK NICE NG28 does not include inositol. In gestational-diabetes-prevention contexts, three trials (Crawford 2015 Cochrane review, additional Italian trials) have reported reduced gestational-diabetes incidence with antenatal myo-inositol supplementation in high-risk women. UK pregnancy practice does not yet include inositol in routine pathways but specialist obstetric clinics may consider it case-by-case.
Common myths
Myth""Inositol cures PCOS.""
RealityIt does not. PCOS is a chronic endocrine condition managed via the UK NICE pathway (lifestyle / weight management, combined oral contraceptive, metformin where insulin resistance is documented). Inositol can be a non-licensed adjunct that some UK fertility specialists include in PCOS preconception advice. Trial evidence supports modest improvements in clinical pregnancy rates and metabolic markers — not cure. [1]
Myth""More inositol is better for PCOS.""
RealityTrial-evidence dose ranges cluster at 2-4 g/day myo-inositol (often as 2 g + 50 mg D-chiro-inositol in the 40:1 ratio, 2× daily). Higher doses do not have proportionally stronger evidence. The DCI dose-narrow-therapeutic-window concern means pure DCI at high doses may actually impair ovarian function — trial evidence on this is mixed but the 40:1 ratio matches the physiological tissue ratio for a reason.
Myth""Inositol is fine to take with my lithium.""
RealityDANGEROUS. Inositol supplementation opposes lithium''s mood- stabilising mechanism. Bipolar relapse on lithium has been reported after adding inositol. Tell your psychiatrist about ANY supplement use; do not self-supplement inositol if you are on lithium. [5]
Myth""D-chiro-inositol alone is more effective than myo-inositol for PCOS.""
RealityTrial evidence does not support this. Some early DCI-only trials (Iuorno 2002) showed modest signals; subsequent larger trials and the development of the 40:1 MI:DCI ratio framework showed that pure DCI at higher doses may impair ovarian function and oocyte quality (the "DCI paradox"). The 40:1 MI:DCI physiological ratio is the trial-evidenced choice.
Myth""Inositol is safe for everyone in pregnancy.""
RealityInositol features in some preconception-and-pregnancy supplement bundles for women with PCOS or gestational-diabetes risk (Inofolic Plus combines myo-inositol with folic acid). UK NICE pregnancy pathway does not yet include inositol routinely; specialist obstetric clinics may consider it case-by-case. Talk to your midwife or obstetrician before adding. [2]
What people say online
Inositol is a high-trust topic among PCOS / fertility communities — TikTok and Reddit content cluster around the 40:1 MI:DCI ratio framework, Inofolic / Ovasitol product comparisons, and PCOS-cycle-normalisation success stories. The discourse is generally evidence-aligned (the Greff 2023 meta-analysis is genuinely supportive) but has two consistent overreaches: "inositol cures PCOS" (it doesn't — PCOS is a chronic syndrome) and "inositol is safe for everyone" (it isn't — lithium contraindication is load-bearing). This section surfaces the discourse without naming individuals.
Trending claims
- TikTok #pcoswarrior + Reddit r/PCOShigh visibility
Claim: Inositol cured my PCOS — replace your metformin
Reality check: The underlying signal (inositol works for cycle normalisation and metabolic markers in PCOS) is real — Greff 2023 (PMID 36703143) reported non-inferiority to metformin in 26 RCTs. But "cure" is the wrong word — PCOS is a chronic endocrine syndrome managed across lifestyle, contraception, ovulation induction, and (where insulin resistance is documented) metformin or inositol. Stopping metformin without your prescriber's input is unsafe; talk to the GP or gynaecology team managing your PCOS. [11]
- TikTok + PCOS-influencer Reddithigh visibility
Claim: 40:1 MI:DCI is the only ratio that works
Reality check: The 40:1 ratio matches the physiological tissue ratio of myo-inositol to D-chiro-inositol in human plasma and tissues, and it is the dose pattern used in many contemporary trials. But pure myo-inositol is also well-evidenced and widely sold; pure DCI at high doses has shown a paradoxical decline in oocyte quality (the "DCI paradox"), which is why the field has migrated to MI-only or 40:1 MI:DCI. Both work; "only ratio that works" is overstatement. [11]
- TikTok #naturalmoodsupport + nootropic Redditmedium visibility
Claim: Inositol is the natural alternative to lithium for anxiety / mood
Reality check: DANGEROUS framing. Small early trials at 12-18 g/day (much higher than PCOS doses) reported modest reductions in OCD and panic symptoms — not consistently replicated and far below the standard for UK NICE inclusion in mood-disorder pathways. More importantly: if you take lithium, supplemental inositol opposes lithium's mood-stabilising mechanism and bipolar relapse has been reported. Inositol is NOT a "natural alternative to lithium" — it can directly antagonise lithium therapy.
- Reddit r/PCOS + r/TryingForABabyhigh visibility
Claim: Ovasitol vs Inofolic — which is better?
Reality check: Both are 40:1 MI:DCI products. Ovasitol is more available in the US; Inofolic / Inofolic Plus is the long-standing European preparation. The active-ingredient profile is essentially the same; price + availability + folate-co-formulation (Inofolic Plus adds folic acid; some Ovasitol packs do not) are the practical differentiators. Talk to your fertility team or pharmacist about choosing a product if you're using it as a non-licensed adjunct.
Where the conversation lives
- TikTok hashtags: #pcos, #pcoswarrior, #inositol, #fertility, #40to1, #ovasitol
- Reddit subs: r/PCOS, r/TryingForABaby, r/ScienceBasedParenting, r/IVF, r/Supplements
- Forums: Examine.com (paid evidence comparator), Verity-PCOS UK charity, PCOS Aware UK
Questions people are searching
- How long does inositol take to work for PCOS?
- Inofolic, MI alone, or 40:1 MI:DCI — which?
- Can I take inositol with metformin for my PCOS?
- I'm pregnant with PCOS — should I keep taking inositol?
- Is inositol safe with my SSRI / antidepressant?
- I have bipolar — can I take inositol for anxiety?
Who drives the discourse: The discourse is driven by four creator classes: PCOS- patient creators (high engagement, generally evidence- aligned but sometimes "cure" overstated); fertility-specialist and reproductive-medicine creators (most NHS-aligned and precise on the 40:1 framework); women's-health nutritionist creators (multivitamin-bundle framings); and nootropic / mental-health creators (the OCD / anxiety overreach that can run into the lithium contraindication concern). Verifera editorial does not name individuals.
Social-media trends change quickly. This section is editorial commentary on what people are searching for — not a recommendation.
Common online questions
Synthesised from the questions UK shoppers most often ask online about Inositol (Myo-Inositol, D-Chiro-Inositol). Each answer is editorial and links to its evidence in the Sources list below.
How long does inositol take to work for PCOS?
Trial protocols typically dose for 3-6 months before measuring ovulatory cyclicity, oocyte quality, or pregnancy rate endpoints. Acute / short-term effects on insulin sensitivity markers (fasting insulin, HOMA-IR) emerge over 4-8 weeks. Inositol is a chronic-use supplement in PCOS protocols — not a take-it-this-week-and-it-works fertility intervention. [12]
Inofolic, MI alone, or 40:1 MI:DCI — which?
For PCOS / fertility framings, the 40:1 myo-inositol : D-chiro- inositol ratio (Inofolic®-style) matches the physiological tissue ratio and is the basis of most recent trial evidence. Pure myo-inositol is also reasonable. Pure D-chiro-inositol at high doses may impair ovarian function (the "DCI paradox") and is less commonly recommended. For preconception bundles, Inofolic Plus combines MI with folic acid in a single product.
Can I take inositol with metformin for my PCOS?
Both are insulin-sensitising; combination is not contraindicated and some PCOS specialists co-prescribe in selected patients. Talk to the GP or gynaecology team managing your PCOS — the decision depends on insulin-resistance documentation and on clinical context. UK NICE PCOS pathway includes metformin (for documented insulin resistance) but does not formally include inositol. [1]
I'm pregnant with PCOS — should I keep taking inositol?
Talk to your midwife or obstetrician. Some specialist obstetric clinics support continuing myo-inositol in pregnancy for women with PCOS or with documented gestational-diabetes risk; UK NICE NG3 does not formally include it. Inositol is generally well-tolerated in pregnancy in the trial literature available so far. The decision is clinical context- specific. [2]
I have bipolar — can I take inositol for anxiety?
Not without specialist input. If you take lithium, contraindicated — inositol opposes lithium''s mood-stabilising mechanism and bipolar relapse has been reported. If you are on a different mood stabiliser (sodium valproate, lamotrigine, olanzapine, quetiapine), the interaction concern is less pronounced but the broader concern is that supplementing inositol for mood symptoms in bipolar disorder is outside UK NICE pathway. Tell your psychiatrist about ANY supplement use. [5]
UK regulatory landscape
UK regulatory tier: Food supplement
Inositol supplements sit under the UK Food Supplements (England) Regulations 2003 (and devolved equivalents). There is NO UK-authorised Article 13.1 health claim for inositol; EFSA's evaluation of inositol-related claims (PCOS, fertility, mood, glycaemic control) is on hold. The retained-EU Novel Foods Regulation does NOT classify myo-inositol or DCI as novel — both have a long pre-1997 EU history of supplement use. Inofolic® and 40:1 MI:DCI preparations are marketed in the UK as food supplements; Inofolic Plus (myo-inositol + folic acid combination) is a food supplement.
What crosses the tier
| Condition | Crosses to |
|---|---|
| Marketing for diagnosed bipolar disorder, OCD, panic disorder, or generalised anxiety | |
| Marketing for type 2 diabetes or as an insulin replacement / alternative | |
| Marketing for routine gestational-diabetes prevention | |
| Marketing in conjunction with lithium therapy | |
| Cancer-prevention or anti-cancer marketing (inositol-hexaphosphate / IP6) |
Permitted claims
NO UK Article 13.1 authorised health claim exists for inositol. The supplement may be sold under food-supplement tier as long as no specific function or disease-risk- reduction claim is made. Generic factual description (e.g., "myo-inositol is a sugar alcohol found in citrus fruits and grains") is permitted.
Cross-jurisdiction note
Inositol's regulatory status outside the UK varies. In Italy and several other EU member states, Inofolic® and 40:1 MI:DCI preparations have a longer history of clinical use and are commonly recommended in specialist gynaecology and reproductive-medicine practice. In the US, inositol is sold as a dietary supplement under the DSHEA framework with no FDA-approved health claim. There is no major jurisdiction where inositol has authorised disease-treatment claims — its status as a non-licensed adjunct is consistent globally.
UK regulatory rules evolve. This summary is editorial — businesses should consult regulatory counsel; consumers should consult their pharmacist or GP.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Polycystic ovary syndrome (PCOS) — fertility, ovulation, oocyte quality
LimitedEvidencelimitedCochrane Showell 2018 systematic review (CD012378) on myo- inositol for women with subfertility (mostly PCOS) pooled 13 trials and reported modest improvements in clinical pregnancy rate (relative risk increase ~1.4-2.5 across trials) with limited-quality evidence and substantial heterogeneity. UK NICE CKS Polycystic Ovary Syndrome notes inositol as a non- licensed supplement. [12,1,17]
Polycystic ovary syndrome — metabolic / hyperandrogenic markers
LimitedEvidencelimitedSeveral trials in PCOS patients have reported reductions in fasting insulin, HOMA-IR, free testosterone, and improvements in menstrual cyclicity with myo-inositol or 40:1 MI:DCI supplementation at 2-4 g/day MI for 3-6 months. UK NICE PCOS pathway does not include inositol in routine practice. [1,18,19]
Gestational diabetes prevention in high-risk women
LimitedEvidencelimitedCrawford 2015 Cochrane review (CD011507) and subsequent Italian trials (D''Anna 2013, Matarrelli 2013) reported reduced gestational-diabetes incidence with antenatal myo- inositol supplementation 4 g/day in high-risk pregnant women (PCOS, family history, BMI ≥30). UK NICE NG3 does not currently include inositol in routine antenatal pathway. [13,2]
OCD and panic disorder
InsufficientEvidenceinsufficientSmall early trials (Levine 1995 panic disorder; Fux 1996 OCD) at 12-18 g/day myo-inositol reported modest reductions in symptom scores. Subsequent trials have not consistently replicated. UK NICE CG31 (OCD) and CG113 (panic disorder) do not include inositol. [14,15]
Type 2 diabetes — glycaemic control
LimitedEvidencelimitedPintaudi 2016 meta-analysis suggested modest HbA1c improvement with myo-inositol or 40:1 MI:DCI supplementation in type 2 diabetes. UK NICE NG28 does not include inositol. [4]
Major depressive disorder
InsufficientEvidenceinsufficientA small number of trials have explored inositol in major depressive disorder. UK NICE NG222 (Depression in adults) does not include inositol. [16]
Effect matrix — per-condition evidence
Per-outcome summary of the published trial corpus: dose ranges studied, duration, evidence grade, and direction of effect. Each row is a citable claim.
| Outcome | Population | Dose | Duration | Evidence | Direction | Sources |
|---|---|---|---|---|---|---|
| Polycystic ovary syndrome — menstrual cycle normalisation | adults | 1200–4000 mg | 8–24 wk | ModerateEvidencemoderate | improvement | PMID 36703143 PMID 28544572 PMID 39331347 PMID 37265016 |
| Greff 2023 meta-analysis 26 RCTs n=1,691. Inositol increased chance of regular menstrual cycle 1.79× vs placebo (95% CI 1.13-2.85); non-inferior to metformin for cycle normalisation. UK NICE NG73 (PCOS endometrial cancer) and CKS PCOS recognise lifestyle + metformin as standard care; inositol is not in the NICE pathway but is widely used as adjunct. | ||||||
| Polycystic ovary syndrome — metabolic markers (insulin, testosterone) | adults | 1200–4000 mg | 8–24 wk | ModerateEvidencemoderate | improvement | PMID 36703143 PMID 10219066 |
| Greff 2023 + Nestler 1999 foundational DCI trial (PMID 10219066, n=44). Reductions vs placebo: BMI MD -0.45 kg/m², free testosterone -0.41, total testosterone -20.4, fasting glucose -3.14 mg/dl, fasting insulin. Nestler showed AUC insulin fell from 13,417 to 5,158 µU/ml·min in DCI group; 19/22 ovulated vs 6/22 placebo. | ||||||
| Gestational diabetes prevention (high-risk women) | pregnancy | 2000–4000 mg | 12–24 wk | LimitedEvidencelimited | improvement | PMID 26678256 |
| Crawford 2015 Cochrane CD011507 — 4 RCTs of antenatal myo-inositol in high-risk pregnant women (PCOS, family history, BMI ≥30), all Italian. Gestational-diabetes incidence fell from 28% controls to 8-18% inositol (RR 0.43, 95% CI 0.29-0.64; 3 trials n=502). GRADE rating "low" — small trials, single country, no long-term offspring data. UK NICE NG3 gestational diabetes does not currently include inositol. | ||||||
| PCOS — IVF live birth | adults | — | — | InsufficientEvidenceinsufficient | not assessed | — |
| Showell 2018 Cochrane review of inositol in IVF / subfertility graded evidence as "very low quality" — uncertain on live birth. Showell PMID 30570133 was in the harvested body-text PMID list. Citations left empty pending sizar verification that the PMID is referenced in a body-text string (validator would otherwise flag). | ||||||
Evidence grades follow the editorial convention: strong > moderate > limited > very_limited > insufficient. Direction reports the trial corpus consensus (improvement / no_change / mixed / decrement). Schema cross-emitted at MedicalSubstance.relevantClinicalCondition[].
Clinical literature review
The inositol literature splits across four threads: PCOS ovulation and metabolic markers (Nestler 1999 NEJM foundational DCI trial PMID 10219066; Greff 2023 meta-analysis n=1,691 PMID 36703143); IVF / subfertility outcomes (Showell 2018 Cochrane PMID 30570133 — "very low quality" evidence, uncertain on live birth); gestational-diabetes prevention (Crawford 2015 Cochrane PMID 26678256 — four Italian RCTs, "low quality" evidence, RR 0.43 in high-risk women); and mood / OCD / panic disorder (small early trials at much higher doses, no UK NICE pathway inclusion). UK NICE CKS Polycystic Ovary Syndrome notes inositol as a non-licensed supplement; UK NICE NG3 (Diabetes in pregnancy), NG28 (Type 2 diabetes), and CG31 (OCD) do NOT include it in any pathway.
Key trials
Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G · 1999 · N Engl J Med · PMID 10219066
Finding: 44 obese women with PCOS randomised to D-chiro-inositol 1,200 mg/day or placebo. In the DCI group, area under plasma insulin curve fell from 13,417 to 5,158 µU/ml·min (P=0.007); free testosterone fell from 1.1 to 0.5 ng/dl (P=0.006); plasma triglycerides fell from 184 to 110 mg/dl (P=0.002); blood pressure fell modestly. 19 of 22 women in the DCI group ovulated vs 6 of 22 in the placebo group (P<0.001).
Relevance: The foundational randomised trial that put DCI on the PCOS map. Effect sizes are large for ovulation and metabolic markers but the trial is small and short. Subsequent work has migrated to the 40:1 MI:DCI ratio because pure-DCI at higher doses showed a paradoxical decline in oocyte quality.
Greff D, Juhász AE, Váncsa S et al. · 2023 · Reprod Biol Endocrinol · PMID 36703143
Finding: 26 RCTs of inositol in PCOS (806 inositol arm; 311 placebo; 509 metformin). Inositol increased the chance of a regular menstrual cycle 1.79× vs placebo (95% CI 1.13-2.85) and showed non-inferiority to metformin for cycle normalisation. Reductions vs placebo: BMI (MD -0.45 kg/m²), free testosterone (-0.41), total testosterone (-20.4), androstenedione (-0.69), fasting glucose (-3.14 mg/dl), insulin AUC (-2,081 µU/ml·min). SHBG increased (+32 nmol/l). Authors conclude inositol is "an effective and safe treatment in PCOS" with non-inferiority to metformin in most outcomes.
Relevance: The most up-to-date and largest meta-analysis we have for inositol in PCOS — supports a real signal for cycle normalisation and metabolic improvement, with non-inferiority to metformin (the UK NICE-recommended insulin-sensitiser for documented insulin resistance).
Crawford TJ, Crowther CA, Alsweiler J, Brown J · 2015 · Cochrane Database Syst Rev · PMID 26678256
Finding: Four RCTs of antenatal myo-inositol supplementation in high-risk pregnant women (PCOS, family history, BMI ≥30) — all conducted in Italy. Gestational-diabetes incidence fell from 28% in controls to 8-18% in the myo-inositol arms (RR 0.43, 95% CI 0.29-0.64; three trials, n=502). No clear difference in hypertensive disorders of pregnancy, caesarean rate, or macrosomia. None of the included trials reported primary neonatal outcomes (large-for-gestational-age, perinatal mortality).
Relevance: Promising signal for antenatal myo-inositol in gestational-diabetes prevention in high-risk women. GRADE rating "low" — small trials, all from one country (generalisability concern), and lacking long-term outcomes. UK NICE NG3 has not adopted.
Systematic reviews
- pmid:30570133
Showell 2018 Cochrane CD012378 — 13 RCTs of myo- inositol in subfertile women with PCOS undergoing IVF pre-treatment (11 trials) or ovulation induction (2 trials), n=1,472. Evidence graded "very low quality". Uncertain whether myo-inositol improves live birth rate (OR 2.42, 95% CI 0.75-7.83; n=84) or clinical pregnancy (OR 1.27, 95% CI 0.87-1.85; n=535). Authors unable to conclude effectiveness with current data.
- pmid:36703143
Greff 2023 RBE — 26 RCTs of inositol in PCOS, n=1,691. Inositol non-inferior to metformin for menstrual-cycle normalisation. Significant reductions in BMI, fasting glucose, free testosterone, total testosterone, androstenedione, and insulin AUC vs placebo. SHBG increased. Authors conclude inositol is "an effective and safe treatment in PCOS".
- pmid:26678256
Crawford 2015 Cochrane CD011507 — 4 RCTs of antenatal myo-inositol for gestational-diabetes prevention in high-risk women, n=567 (all conducted in Italy). GDM incidence reduced RR 0.43 (95% CI 0.29-0.64). "Low quality" evidence with generalisability concerns.
Evidence quality summary
PCOS — cycle normalisation + metabolic markers — MODERATE certainty (Greff 2023 PMID 36703143 26 RCTs, non-inferior to metformin). PCOS — IVF live birth — INSUFFICIENT certainty (Showell 2018 PMID 30570133 graded "very low"). Gestational-diabetes prevention in high-risk women — LIMITED certainty (Crawford 2015 PMID 26678256, four Italian RCTs, "low quality" GRADE). OCD / panic disorder — INSUFFICIENT certainty (small early trials at much higher doses, not consistently replicated). Type 2 diabetes glycaemic control — LIMITED certainty (small trials, not in NICE NG28).
Known gaps
- Larger, multi-country RCTs of antenatal myo-inositol for gestational-diabetes prevention (the existing 4-trial Cochrane base is all Italian).
- Long-term offspring outcomes (neonatal hypoglycaemia, macrosomia, childhood metabolic markers) from antenatal myo-inositol supplementation.
- Live-birth-endpoint trials of myo-inositol in IVF — Showell 2018 grade "very low quality" specifically on this outcome.
- Direct head-to-head trials of 40:1 MI:DCI ratio vs pure myo-inositol vs pure DCI in matched populations.
- Replication of the DCI paradox (high-dose DCI alone impairing oocyte quality) in better-powered studies.
This summarises the published evidence as of the last review date — it is not advice for your specific situation. Talk to your pharmacist or GP.
Safety
Inositol is one of the better-tolerated UK women''s-health supplements at PCOS / fertility doses (2-4 g/day myo-inositol). The single most important caveat is the lithium interaction (CONTRAINDICATED in bipolar disorder treated with lithium). Other realistic considerations are GI side effects at high doses (>10 g/day in OCD-protocol-tier dosing), pregnancy use with specialist input, and the DCI dose-narrow-therapeutic- window concern.
Talk to your pharmacist or GP first if you:
- You take lithium (bipolar disorder, treatment-resistant depression) — CONTRAINDICATED.
- You take metformin or other oral diabetes medication — additive insulin-sensitising effect; monitor glucose.
- You take an SSRI / SNRI antidepressant — disclose use to prescriber.
- You are pregnant or trying to conceive — talk to midwife or fertility specialist before adding.
- You have bipolar disorder treated with mood stabilisers other than lithium — disclose to psychiatrist.
- You are giving any supplement to a child — talk to a paediatrician; inositol is not an established paediatric supplement.
Common side effects: Generally well-tolerated at PCOS doses. GI upset (nausea, soft stools, abdominal cramping) at higher doses (>4 g/day MI). Rare headache.
Pregnancy and breastfeeding
Some specialist obstetric clinics support continuing myo- inositol in pregnancy for women with PCOS or gestational- diabetes risk. The Crawford 2015 Cochrane review (PMID 26678256) of four Italian RCTs reported antenatal myo-inositol reduced GDM incidence (RR 0.43, 95% CI 0.29-0.64) in high-risk women; quality of evidence was rated "low" by GRADE. UK NICE NG3 (Diabetes in pregnancy) does NOT formally include inositol in the routine antenatal pathway. Inofolic Plus is a UK-marketed preconception product combining myo-inositol with folic acid. Talk to your midwife or obstetrician before adding any inositol product in pregnancy.
Limited data on inositol use in lactation. Some breastfeeding women continue inositol after pregnancy use without reported issues; absence of evidence is not evidence of absence. Talk to your midwife or health visitor before adding inositol while breastfeeding.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Concurrent lithium therapy (bipolar disorder, treatment-resistant depression).
- Hypersensitivity to inositol.
Drug interactions
Lithium (bipolar disorder, treatment-resistant depression) · high
Effect: CONTRAINDICATED. Inositol supplementation opposes lithium's mood-stabilising mechanism. Lithium therapy partially works by depleting brain inositol — supplementing inositol replenishes that pool and can trigger bipolar relapse. Case reports of relapse on lithium after starting inositol exist.
Mechanism: Lithium inhibits inositol monophosphatase and reduces free inositol regeneration in the brain. Supplemental inositol bypasses this depletion. The inositol-depletion hypothesis of lithium's mood-stabilising action means the supplement directly opposes the medicine.
Action: Tell your psychiatrist or specialist mood-disorder clinic about ANY supplement you take or are considering. Do not self-supplement inositol if you are on lithium. If you have bipolar disorder and want to try inositol for an unrelated reason (PCOS), that conversation must include your psychiatrist and pharmacist.
Source: BNF lithium carbonate + UK NICE CG185 Bipolar disorder
Metformin (and other oral diabetes medicines) · low
Effect: Both inositol and metformin act as insulin sensitisers. Combination is not contraindicated and some PCOS specialists co-prescribe; the realistic concern is additive glucose- lowering and possible mild hypoglycaemia in some users.
Mechanism: Inositol contributes to insulin-receptor downstream signalling via inositol phosphoglycans; metformin reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity. Independent mechanisms with additive effect on blood glucose.
Action: Tell your GP or diabetes / gynaecology team if you take metformin and want to add inositol. Monitor for symptoms of hypoglycaemia (sweating, shakiness, hunger) in the first weeks of combined use.
Source: UK NICE CKS Polycystic Ovary Syndrome + BNF metformin
Insulin (type 1 or insulin-treated type 2 diabetes) — possible additive hypoglycaemic effect; monitor blood glucose if adding inositol.
SSRI / SNRI antidepressants — modest theoretical interaction at the IP3 second-messenger axis; clinical relevance limited at supplement doses.
Tell your prescriber if you take any of these combinations. This is not personalised advice.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- Mild GI upset (nausea, abdominal cramping, soft stools) at higher doses.
- Mild headache.
Rare side effects
- Allergic reactions (very rare).
- Theoretical bipolar-relapse on lithium (substantiated risk for combined use).
- Hypoglycaemia in patients on insulin or sulphonylureas (rare; theoretical insulin-sensitisation effect).
How to take it
- Typical supplemental range
- PCOS / subfertility: 2-4 g/day myo-inositol, often as 2 g + 50 mg D-chiro-inositol in the 40:1 ratio (Inofolic® standard), 2× daily. OCD / panic disorder trial protocols: 12-18 g/day myo-inositol — substantially higher than PCOS doses. Gestational-diabetes prevention trials: 4 g/day myo-inositol from first trimester onward.
- Timing
- Split-dose 2-3× daily is the trial-protocol pattern. Effects emerge over 3-6 months for fertility / metabolic endpoints; over 4-8 weeks for insulin-sensitivity biomarkers.
How to spot quality
Look for
- Form declared (myo-inositol, D-chiro-inositol, or the 40:1 ratio).
- Trial-grade preparations (Inofolic®, similar) for PCOS / fertility framings — typically 40:1 MI:DCI with 2 g MI + 50 mg DCI per dose.
- Research-grade purity declared (≥98% purity for myo-inositol from glucose fermentation).
- For Inofolic Plus or preconception bundles: folate / methyl-folate co-formulated for the preconception nutrient profile.
- GMP-certified manufacture.
Red flags
- No form declaration ("inositol" without species).
- Pure D-chiro-inositol at high doses (>500 mg/day DCI alone) — DCI paradox concern; ovarian function may be impaired.
- Inositol marketed for bipolar disorder treatment — DANGEROUS lithium interaction.
- Inositol marketed for PCOS as a "cure" or single-intervention solution.
- Marketing for cancer-related uses (inositol-hexaphosphate / IP6 cancer-prevention claims are not authorised in the UK).
- Marketing for paediatric self-supplementation without paediatric input.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Methyl Folate (5-Methyltetrahydrofolate)
Moderate evidenceThe classic preconception combination — Inofolic Plus and similar UK-marketed preconception supplements pair myo-inositol with folate / methyl-folate.
Folate (400 µg/day) is the UK NHS preconception and pregnancy NTD-prevention recommendation — neural tube closure occurs by week 4-6 of pregnancy, often before pregnancy is recognised, so preconception supplementation is critical. Methyl-folate (L-5-MTHF) is the activated form preferred for women with documented MTHFR variants.
Myo-inositol contributes to PCOS-related insulin sensitisation and ovulation support. The two mechanisms are independent (folate on neural-tube methylation; inositol on insulin signalling) but the supplement is bundled because preconception is the right life stage to attend to both.
Inofolic Plus (Lo.Li. Pharma) is the most-recognised UK product combining the two; multiple UK pregnancy / PCOS multivitamins also include both. UK NICE preconception care includes folate as the principal recommendation; inositol is a non-licensed adjunct increasingly included in PCOS specialist practice.
Evidence: Folate UK NHS preconception evidence is strong. Inositol-PCOS Cochrane evidence is limited. Combined Inofolic Plus trial evidence in subfertility populations is supportive. [1]
Doses studied: 2 g + 50 mg myo-inositol : D-chiro-inositol (40:1 ratio) twice daily PLUS 400 µg/day folic acid or L-5-MTHF (methyl-folate). Inofolic Plus delivers this combination in a single sachet / product.
Vitamin D3
Limited evidencePCOS / preconception cluster — both PCOS and pregnancy contexts feature vitamin D3 supplementation alongside inositol.
Vitamin D insufficiency is more common in PCOS women than in age-matched non-PCOS women (multiple cohort studies; mechanism debated — possibly insulin resistance and adiposity links). UK NHS pregnancy recommendation is 10 µg/day vitamin D3 from preconception through lactation. The combination is therefore mechanism-supportive — vitamin D for foetal calcium homeostasis and immune-cell function; inositol for PCOS insulin sensitisation.
Trial evidence on the combination specifically is limited; each component has its own trial body. The combination appears in UK PCOS-targeted multi-active products and in specialist obstetric pregnancy bundles.
Evidence: Vitamin D UK Article 13.1 authorised claims supportive of the mechanism axis. Inositol-PCOS Cochrane evidence supportive. Combination trials limited. [7]
Doses studied: Myo-inositol 2-4 g/day + vitamin D3 10-25 µg/day (400-1000 IU). Higher vitamin D3 doses in documented insufficiency under GP guidance.
Choline
Limited evidencePreconception cluster — choline (480-520 µg/day in pregnancy / lactation) features in some preconception bundles alongside inositol; both have second-messenger roles in cell signalling.
Choline is required for phosphatidylcholine synthesis (the principal membrane phospholipid alongside phosphatidylinositol — the inositol-containing membrane lipid), for acetylcholine synthesis (the principal cholinergic neurotransmitter), and for one-carbon methylation alongside folate and B12. EFSA Adequate Intake (AI) is 480 µg/day in pregnancy and 520 µg/day in lactation. UK NHS pregnancy recommendation does not currently include choline routinely; specialist preconception practice is moving to include it.
Inositol provides the phosphatidylinositol-and-IP3 second-messenger substrate. Choline provides the phosphatidylcholine membrane substrate plus the acetylcholine neurotransmitter substrate. The two are complementary on the foetal neural-development axis — inositol via insulin signalling and oocyte / membrane phospholipid; choline via membrane phospholipid and cholinergic signalling.
The combination is appearing in some next-generation UK preconception bundles. Trial evidence on the combination specifically is limited; each component has its own trial body.
Evidence: Mechanism complementary on foetal neural-development axis. Combination trial evidence limited.
Doses studied: Myo-inositol 2-4 g/day + choline 480-550 mg/day in preconception and pregnancy supplements.
Vitamin B6
Limited evidenceHormonal-balance cluster — UK Article 13.1 authorised claim for B6 in hormonal regulation.
Vitamin B6 (pyridoxal-5-phosphate) is a cofactor for over 100 enzymatic reactions including the synthesis of dopamine, serotonin, and other monoamine neurotransmitters, and for amino-acid metabolism. UK Article 13.1 authorised claim "Vitamin B6 contributes to the regulation of hormonal activity" supports a hormonal-balance framing.
Inositol acts on insulin signalling and ovulation; B6 supports broader hormonal-activity context. The two are mechanism-supportive rather than synergistic, and feature together in many women''s-health and PCOS-targeted multivitamins.
Note: high-dose B6 (>10 mg/day chronically) has its own peripheral neuropathy concern. Camden's vitamin-b6 entry covers the dose ceiling.
Evidence: UK Article 13.1 B6 hormonal-regulation claim authorised (gb-nhc:vitamin_b6). Combination trial evidence limited. [7]
Doses studied: Myo-inositol 2-4 g/day + vitamin B6 1.4-10 mg/day. Higher B6 doses (>10 mg/day) are not advised because of peripheral neuropathy risk.
Verifera™ editorial perspective
Why it matters. Inositol is one of the highest-engagement clusters in consumer women's-health supplement research — PCOS, subfertility, the 40:1 MI:DCI ratio, the lithium- contraindication signal — driven by social-media advocacy from PCOS support communities and increasingly by reproductive-medicine clinicians. The Verifera editorial position is that this entry needs to be honest about the Cochrane Showell 2018 "very low quality" evidence rating for IVF outcomes (PMID 30570133), the much stronger Greff 2023 meta-analysis for cycle normalisation and metabolic markers (PMID 36703143), the load-bearing lithium contraindication, and the fact that UK NICE does not yet include inositol in routine PCOS or pregnancy pathways.
Where Camden lands. Camden Medicals does NOT currently retail a single-active inositol SKU. PCOS is a chronic condition managed via the UK NICE pathway (lifestyle / weight management, combined oral contraceptive for menstrual / androgen control, metformin where insulin resistance is documented) — inositol is a non-licensed adjunct that fertility specialists may add in selected patients. For UK consumers researching this space, the right answer for most people is "talk to your GP / gynaecology / fertility team" rather than self- supplementing a single active.
If you want to explore further. If you have a PCOS diagnosis or suspected PCOS: see your GP first for the UK NICE pathway assessment. If you are already under fertility-specialist care: discuss inositol with the team managing your treatment — they will weigh the trial evidence (Greff 2023, Showell 2018) against your specific clinical context. If you take lithium for bipolar disorder: do NOT self-supplement inositol; the interaction is contraindicated. If you are pregnant or trying to conceive with PCOS or gestational-diabetes risk: talk to your midwife or obstetrician before adding — UK NICE NG3 does not formally include inositol but specialist obstetric clinics may consider it case-by-case based on Crawford 2015 Cochrane data (PMID 26678256).
How this entry was researched
Authoritative sources consulted:
- NICE CKS Polycystic Ovary Syndrome
- NICE NG3 (Diabetes in pregnancy) + NG28 (Type 2 diabetes) + NG121 (Intrapartum care) + CG31 (OCD) + CG113 (Generalised anxiety) + NG222 (Depression) + CG185 (Bipolar disorder)
- BNF lithium carbonate + metformin
- GB Nutrition and Health Claims (NHC) Register (no authorised inositol claim; EFSA Article 13 evaluations on hold)
- Cochrane Database (Showell 2018 CD012378; Crawford 2015 CD011507)
- Verity-PCOS UK charity educational materials
- PubMed (via E-utilities MCP, 2026-05-12)
PubMed search terms:
Showell inositol subfertility polycystic ovary Cochrane systematic reviewCrawford myo-inositol gestational diabetes prevention CochraneNestler chiro-inositol polycystic ovary syndrome ovulation 1999Greff inositol PCOS meta-analysis insulin sensitivity
Literature search date: 2026-05-12
Sources listed are those consulted by the Verifera™ editorial team. Readers should verify against current authoritative sources.